Core Viewpoint - The biopharmaceutical company, Aikang Pharmaceutical-B (2617.HK), has shown strong performance, with its stock price surging over 15 times since its IPO, reaching a market capitalization exceeding HKD 80 billion [1]. Company Overview - Aikang Pharmaceutical was listed on June 23 this year and focuses on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [1]. - The company's core product, Tinengotinib, is a unique MTK inhibitor currently in the registration clinical stage, targeting several recurrent or refractory solid tumors [1]. Stock Performance - The stock price of Aikang Pharmaceutical increased by 95% during trading, reaching HKD 212.6, with a significant rise from the IPO price of HKD 13.15 [1]. - The stock has experienced a remarkable increase in value, reflecting strong investor interest and confidence in the company's future prospects [1].
上市不到3个月股价飙升超15倍！药捷安康市值升破800亿港元
Ge Long Hui·2025-09-12 07:46